UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
(Amendment No. 2)
Under the Securities Exchange Act of 1934
MUSCLEPHARM CORP.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
627335201
(CUSIP Number)
Wynnefield Partners Small Cap Value, L.P.
I
450 Seventh Avenue, Suite 509
New York, New York 10123
Attention: Mr. Nelson Obus
|
Copy to:
Jeffrey S. Tullman, Esq.
Kane Kessler, P.C.
1350 Avenue of the Americas, 26th
Floor
New York, New York 10019
(212) 541-6222 |
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
June 19, 2015
(Date of Event which requires Filing of
this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨
CUSIP No. 627335201
|
13D/A |
Page 2 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Wynnefield Partners Small Cap Value, L.P. I 13-3953291
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
271,668 (See Item 5) |
8 |
SHARED VOTING POWER
0 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
271,668 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
0 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
271,668 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2% |
14
|
TYPE OF REPORTING PERSON*
PN |
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 3 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Wynnefield Partners Small Cap Value, L.P. 13-3688497
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
178,833 (See Item 5) |
8 |
SHARED VOTING POWER
0 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
178,833 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
0 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
178,833 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.3% |
14
|
TYPE OF REPORTING PERSON*
PN
|
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 4 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Wynnefield Small Cap Value Offshore Fund, Ltd.
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
149,499 (See Item 5) |
8 |
SHARED VOTING POWER
0 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
149,499 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
0 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
149,499 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.1% |
14
|
TYPE OF REPORTING PERSON*
CO
|
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 5 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Wynnefield Capital, Inc. Profit Sharing Plan
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
40,000 (See Item 5) |
8 |
SHARED VOTING POWER
0 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
40,000 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
0 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
40,000 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.3% |
14
|
TYPE OF REPORTING PERSON*
CO |
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 6 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Wynnefield Capital Management, LLC 13-4018186
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
N/A |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
New York
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
450,501 (See Item 5) |
8 |
SHARED VOTING POWER
0 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
450,501 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
0 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
450,501 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.3% |
14
|
TYPE OF REPORTING PERSON*
OO |
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 7 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Wynnefield Capital, Inc. 13-3688495
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
N/A |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
149,499 (See Item 5) |
8 |
SHARED VOTING POWER
0 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
149,499 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
0 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
149,499 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.1% |
14
|
TYPE OF REPORTING PERSON*
CO
|
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 8 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Nelson Obus
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
N/A |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
40,000 (See Item 5) |
8 |
SHARED VOTING POWER
600,000 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
40,000 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
600,000 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
640,000 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.7% |
14
|
TYPE OF REPORTING PERSON*
IN
|
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 9 of 12 |
1 |
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Joshua Landes
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x |
3 |
SEC USE ONLY
|
4 |
SOURCE OF FUNDS*
N/A |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
0 (See Item 5) |
8 |
SHARED VOTING POWER
600,000 (See Item 5) |
9 |
SOLE DISPOSITIVE POWER
0 (See Item 5) |
10 |
SHARED DISPOSITIVE POWER
600,000 (See Item 5) |
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
600,000 (See Item 5) |
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*
¨ |
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.4% |
14
|
TYPE OF REPORTING PERSON*
IN
|
|
|
|
|
CUSIP No. 627335201
|
13D/A |
Page 10 of 12 |
This Amendment
No. 2 amends the Statement of Beneficial Ownership on Schedule 13D originally filed with the Securities and Exchange
Commission (the “Commission”) on April 20, 2015 and as further amended by Amendment No. 1 filed on June 9, 2015
(collectively, the “Schedule 13D”) by the Wynnefield Reporting Persons (as defined in the Schedule 13D) with
respect to shares of common stock, $0.001 par value per share (the “Common Stock”) of MusclePharm Corp., a
Nevada corporation (the “Issuer”), whose principal executive office are located at 4721 Ironton Street, Building
A, Denver, Colorado 80239. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the
Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is hereby amended and restated as
follows:
The securities reported in this Schedule 13D as directly beneficially owned by the Wynnefield Reporting
Persons were acquired with funds of approximately $5,943,605. All such funds were provided from the working capital or personal
funds of the Wynnefield Reporting Persons who directly beneficially own such securities.
Item 4. Purpose of the Transaction
Item 4 of the
Schedule 13D is hereby amended and restated as follows:
On June 8, 2015 the Wynnefield Reporting
Persons sent the Issuer’s Board and CEO a letter, which was filed as an exhibit to our Schedule 13D filed with the Securities
and Exchange Commission (the “SEC”) on June 9, 2015, asking the Board to take the following actions by June 19, 2015:
| 1) | “Issue an immediate press release correcting any material misstatements regarding the Company’s current liquidity
and cash flow position. |
| 2) | Announce the opening of a window for shareholder submission of nominees for election to the Company’s Board, including
nominees to fill the newly created seventh board seat, in accordance with Nevada corporate law. |
| 3) | Provide a full explanation surrounding the mass resignation and replacement of the three independent directors of the Company. |
| 4) | Engage a qualified investment bank to assist management and the Board to fully explore all strategic opportunities to increase
shareholder value, including auction of the Company.” |
We did this because of concerns arising
from the contradictory or disturbing filings and announcements that the Issuer has made during 2015. Our requests were met with
total radio silence.
This has
heightened our fears that, in our opinion, the Issuer, absent a dilutive capital infusion which would have a negative impact
on current investors, may not be able to continue as a “going concern” for much longer. As a result, we
determined to sell 400,000 shares of Common Stock representing 38% of our position to an unrelated buyer. This reduced our exposure and enabled us to realize a much needed capital loss in a year in which our sales
of shares of some portfolio companies have generated significant capital gains.
However, the Issuer’s Board and management
would be making a colossal error were they to assume that the Wynnefield Reporting Persons have diminished to any degree their
determination to hold Issuer’s Board and management accountable to basic governance standards and SEC disclosure requirements.
The Wynnefield Reporting Persons are committed to continuing to press Issuer’s Board and management to act in the best interests
of the Issuer’s outside shareholders.
Other than as set forth
in this Item 4, the Wynnefield Reporting Persons do not have any current plans, proposals or negotiations that relate to or would
result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Wynnefield Reporting Persons
intend to review their investment in the Issuer on a continuing basis, and to the extent permitted by law, may seek to engage in
discussions with other stockholders and/or with management and the Board of the Issuer concerning the business, operations or future
plans of the Issuer. Depending on various factors including, without limitation, the Issuer’s financial position, the price
levels of the shares of Common Stock, conditions in the securities markets and general economic and industry conditions, the Wynnefield
Reporting Persons may, in the future take such actions with respect to their investment in the Issuer as they deem appropriate
including, without limitation, purchasing additional shares of Common Stock, selling shares of Common Stock, engaging in short
selling of or any hedging or similar transaction with respect to the Common Stock, taking any other action with respect to the
Issuer or any of its securities in any manner permitted by law or changing its intention with respect to any and all matters referred
to in paragraphs (a) through (j) of Item 4.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Schedule 13D is hereby amended and restated as
follows:
(a), (b) and (c) As of June 24, 2015, the Wynnefield Reporting
Persons beneficially owned in the aggregate 640,000 shares of Common Stock, constituting approximately 4.7% of the outstanding
shares of Common Stock. The percentage of shares of Common Stock reported as being beneficially owned by the Wynnefield Reporting
Persons is based upon 13,492,191 shares outstanding as of May 1, 2015, as set forth in the Issuer’s Quarterly Report on Form
10-Q for the quarter ended March 31, 2015, filed with the Securities and Exchange Commission (the “Commission”) on May
11, 2015.
CUSIP No. 627335201
|
13D/A |
Page 11 of 12 |
The following table sets forth certain information with respect
to Common Stock directly beneficially owned by the Wynnefield Reporting Persons listed below:
Name |
Number of Common Stock |
Percentage of Outstanding Common Stock |
Wynnenfield Partners I |
271,668 |
2% |
Wynnefield Partners |
178,833 |
1.3% |
Wynnefield Offshore |
149,499 |
1.1% |
Plan |
40,000 |
.3% |
WCM is the sole general partner of Wynnefield Partners and Wynnefield
Partners I and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under
the Exchange Act) of the Common Stock that Wynnefield Partners and Wynnefield Partners I beneficially own. WCM, as the sole general
partner of Wynnefield Partners and Wynnefield Partners I, has the sole power to direct the voting and disposition of the Common
Stock that Wynnefield Partners and Wynnefield Partners I beneficially own. Messrs. Obus and Landes are the co-managing members
of WCM and, accordingly, each of Messrs. Obus and Landes may be deemed to be the indirect beneficial owner (as that term is defined
under Rule 13d-3 under the Exchange Act) of the Common Stock that WCM may be deemed to beneficially own. Each of Messrs. Obus and
Landes, as co-managing members of WCM, share the power to direct the voting and disposition of the shares of Common Stock that
WCM may be deemed to beneficially own.
WCI is the sole investment manager of Wynnefield Offshore and,
accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act)
of the Common Stock that Wynnefield Offshore beneficially owns. WCI, as the sole investment manager of Wynnefield Offshore, has
the sole power to direct the voting and disposition of the Common Stock that Wynnefield Offshore beneficially owns. Messrs. Obus
and Landes are executive officers of WCI and, accordingly, each may be deemed to be the indirect beneficial owner (as that term
is defined under Rule 13d-3 under the Exchange Act) of the Common Stock that WCI may be deemed to beneficially own. Messrs. Obus
and Landes, as executive officers of WCI, share the power to direct the voting and disposition of the shares of Common Stock that
WCI may be deemed to beneficially own.
The Wynnefield Profit Plan is an employee profit sharing plan.
Mr. Obus is the portfolio manager of the Wynnefield Profit Plan and has the sole authority to direct the voting and the disposition
of the shares of Common Stock that the Wynnefield Profit Plan beneficially owns. Accordingly, Mr. Obus may be deemed to be the
indirect beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act) of the shares of Common Stock that
the Wynnefield Profit Plan may be deemed to beneficially own.
Beneficial ownership of the Common Stock shown on the cover
pages of and set forth elsewhere in this Schedule 13D/A for each member of the Wynnefield Reporting Persons assumes that they have
not formed a group for purposes of Section 13(d)(3) under the Exchange Act, and Rule 13d-5(b)(1) promulgated thereunder. If the
members of the Wynnefield Reporting Persons were deemed to have formed a group for purposes of Section 13(d)(3) and Rule 13d-5(b)(1),
the group would be deemed to own beneficially (and may be deemed to have shared voting and dispositive power over) in the aggregate
640,000 shares of Common Stock, constituting approximately 4.7% of the outstanding shares of Common Stock. The percentage of shares
of Common Stock reported as being beneficially owned by the Wynnefield Reporting Persons is based upon 13,492,191 shares outstanding
as of May 1, 2015, as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, filed
with the Securities and Exchange Commission (the “Commission”) on May 11, 2015.
The filing of this Schedule 13D and any future amendment by the Wynnefield Reporting Persons, and the
inclusion of information herein and therein with respect to WCM, WCI and Messrs. Obus and Landes, shall not be considered an admission
that any of such persons, for the purpose of Section 16(b) of the Exchange Act, are the beneficial owners of any shares in which
such persons do not have a pecuniary interest. Each of WCM, WCI and Messrs. Obus and Landes disclaims any beneficial ownership
of the shares covered by this Schedule 13D/A.
The Wynnefield Reporting Persons have sold shares of Common
Stock during the last 60 days, as follows:
Name |
Date |
Number of Shares |
Price Per Share |
|
|
|
|
Wynnefield Partners I |
June 19, 2015 |
202,440 |
$5.48 |
|
|
|
|
Wynnefield Partners |
June 19, 2015 |
121,120 |
$5.48 |
|
|
|
|
Wynnefield Offshore |
June 19, 2015 |
76,440 |
$5.48 |
| (e) | On June 19, 2015, the Wynnefield Reporting Persons ceased
to be the beneficial owner of more than 5% of the Common Stock. |
CUSIP No. 627335201
|
13D/A |
Page 12 of 12 |
SIGNATURE
After reasonable inquiry and to the best
of their knowledge and belief, the undersigned certify that the information set forth in this Schedule 13D/A is true, complete and
correct.
Dated: June 24, 2015
WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P. I
By: Wynnefield Capital Management, LLC,
its General Partner
By: /s/ Nelson Obus
Nelson Obus, Co-Managing Member
WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P.
By: Wynnefield Capital Management, LLC,
its General Partner
By: /s/ Nelson Obus
Nelson Obus, Co-Managing Member
WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND, LTD.
By: Wynnefield Capital, Inc.,
its Investment Manager
By: /s/ Nelson Obus
Nelson Obus, President
WYNNEFIELD CAPITAL INC. PROFIT SHARING PLAN, INC.
By: /s/ Nelson Obus
Nelson Obus, Authorized Signatory
WYNNEFIELD CAPITAL MANAGEMENT, LLC
By: /s/ Nelson Obus
Nelson Obus, Co-Managing Member
WYNNEFIELD CAPITAL, INC.
By: /s/ Nelson Obus
Nelson Obus, President
/s/ Nelson Obus
Nelson Obus, Individually
/s/ Joshua Landes
Joshua Landes, Individually
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2024 to May 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From May 2023 to May 2024